Eris Lifesciences Past Earnings Performance
Past criteria checks 2/6
Eris Lifesciences has been growing earnings at an average annual rate of 4.8%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 17.2% per year. Eris Lifesciences's return on equity is 11.5%, and it has net margins of 14%.
Key information
4.8%
Earnings growth rate
4.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 17.2% |
| Return on equity | 11.5% |
| Net Margin | 14.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Eris Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 24,853 | 3,485 | 4,773 | 0 |
| 30 Jun 24 | 22,469 | 3,803 | 4,323 | 0 |
| 31 Mar 24 | 19,913 | 3,920 | 4,217 | 0 |
| 31 Dec 23 | 18,406 | 3,864 | 3,958 | 0 |
| 30 Sep 23 | 17,750 | 3,856 | 3,841 | 0 |
| 30 Jun 23 | 17,298 | 3,824 | 3,721 | 0 |
| 31 Mar 23 | 16,618 | 3,822 | 3,548 | 0 |
| 31 Dec 22 | 15,663 | 3,970 | 3,362 | 0 |
| 30 Sep 22 | 14,766 | 3,959 | 3,104 | 0 |
| 30 Jun 22 | 13,746 | 3,940 | 2,773 | 0 |
| 31 Mar 22 | 13,262 | 4,061 | 2,622 | 0 |
| 31 Dec 21 | 12,993 | 3,941 | 2,572 | 0 |
| 30 Sep 21 | 12,763 | 3,834 | 2,553 | 0 |
| 30 Jun 21 | 12,482 | 3,728 | 2,377 | 0 |
| 31 Mar 21 | 11,926 | 3,551 | 2,439 | 0 |
| 31 Dec 20 | 11,625 | 3,432 | 2,790 | 0 |
| 30 Sep 20 | 11,192 | 3,165 | 2,717 | 0 |
| 30 Jun 20 | 10,744 | 3,015 | 2,156 | 0 |
| 31 Mar 20 | 10,582 | 2,965 | 2,317 | 0 |
| 31 Dec 19 | 10,252 | 2,943 | 2,520 | 0 |
| 30 Sep 19 | 10,119 | 3,110 | 2,470 | 0 |
| 30 Jun 19 | 9,920 | 3,036 | 1,887 | 0 |
| 31 Mar 19 | 9,672 | 2,908 | 2,453 | 0 |
| 31 Dec 18 | 9,851 | 2,925 | 2,304 | 0 |
| 30 Sep 18 | 9,442 | 2,870 | 2,258 | 0 |
| 30 Jun 18 | 9,212 | 2,945 | 1,708 | 0 |
| 31 Mar 18 | 8,196 | 2,941 | 2,027 | 0 |
| 31 Dec 17 | 8,026 | 2,800 | 1,931 | 0 |
| 30 Sep 17 | 7,781 | 2,735 | 1,818 | 0 |
| 30 Jun 17 | 7,277 | 2,505 | 1,787 | 0 |
| 31 Mar 17 | 7,205 | 2,468 | 1,737 | 0 |
| 31 Mar 16 | 5,967 | 1,112 | 1,746 | 0 |
| 31 Mar 15 | 5,456 | 892 | 1,632 | 0 |
| 31 Mar 14 | 5,088 | 704 | 1,664 | 0 |
Quality Earnings: 540596 has high quality earnings.
Growing Profit Margin: 540596's current net profit margins (14%) are lower than last year (21.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 540596's earnings have grown by 4.8% per year over the past 5 years.
Accelerating Growth: 540596's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 540596 had negative earnings growth (-9.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).
Return on Equity
High ROE: 540596's Return on Equity (11.5%) is considered low.